Back
Halozyme Therapeutics, Inc. Stock Predictions
This Tech Company Grew 32,481%...
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
68
HALO
Halozyme Therapeutics, Inc.
Last Price:
$68.44
Seasonality Move:
5.49%
7 Day Trial
ALL ACCESS PASS
$
7
Halozyme Therapeutics, Inc. Stock Forecast
-
Over the next 52 weeks, Halozyme Therapeutics, Inc. has on average historically risen by 36.4% based on the past 21 years of stock performance.
-
Halozyme Therapeutics, Inc. has risen higher in 12 of those 21 years over the subsequent 52-week period, corresponding to a historical accuracy of 57.14%
-
Is Halozyme Therapeutics, Inc. Stock Undervalued?The current Halozyme Therapeutics, Inc. [HALO] share price is $68.41. The Score for HALO is 68, which is 36% above its historic median score of 50, and infers lower risk than normal.
-
HALO is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
Will Halozyme Therapeutics, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Halozyme Therapeutics, Inc. has on average historically risen by 36.4% based on the past 21 years of stock performance.
Halozyme Therapeutics, Inc. Stock Rating
Buy
68
Halozyme Therapeutics, Inc. (HALO)
is a Buy
Is Halozyme Therapeutics, Inc. overpriced?
-
Halozyme Therapeutics, Inc. has risen higher in 12 of those 21 years over the subsequent 52-week period, corresponding to a historical accuracy of 57.14%
Halozyme Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
halozyme.com
52-Week Data
52-Week High:
79.50
52-Week Low:
46.76
Prediction Charts
Market Cap:
8B
Price in USD:
68.41
Volume:
428.2K
Beta:
1.40
Technical Analysis
SMA50:
67.14
SMA100:
69.10
SMA200:
63.50
52-Wk Change:
43.9%
Stock Predictions
-
Is Halozyme Therapeutics, Inc. stock public?Yes, Halozyme Therapeutics, Inc. is a publicly traded company.
-
What is the Halozyme Therapeutics, Inc. stock quote today?The Halozyme Therapeutics, Inc. stock price is 68.41 USD today.
-
How to buy Halozyme Therapeutics, Inc. stock online?You can buy Halozyme Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Dec-5 | 62.81 | 63.33 | 63.98 | 62.59 |
| Dec-8 | 63.80 | 62.88 | 64.98 | 62.47 |
| Dec-9 | 62.47 | 61.87 | 63.40 | 61.71 |
| Dec-10 | 62.10 | 62.65 | 62.90 | 61.63 |
| Dec-11 | 62.80 | 61.90 | 63.26 | 61.23 |
| Dec-12 | 61.93 | 62.21 | 62.64 | 61.28 |
| Dec-15 | 62.14 | 63.45 | 63.52 | 61.69 |
| Dec-16 | 63.24 | 64.47 | 64.90 | 62.98 |
| Dec-17 | 64.81 | 65.77 | 66.60 | 64.78 |
| Dec-18 | 65.98 | 65.11 | 66.00 | 64.87 |
| Dec-19 | 65.28 | 67.35 | 67.53 | 65.11 |
| Dec-22 | 66.79 | 68.16 | 69.28 | 66.36 |
| Dec-23 | 68.44 | 68.36 | 69.15 | 67.95 |
| Dec-24 | 68.72 | 68.41 | 69.01 | 68.32 |
Halozyme Therapeutics, Inc. Earnings
Halozyme Therapeutics, Inc. Earnings Report: Per Share Halozyme Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Halozyme Therapeutics, Inc. Forecast Revenue Growth
Halozyme Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Halozyme Therapeutics, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $0.31 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.13 per share, and an increase next year of $1.88 per share.
* Halozyme Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.